Agios Pharmaceuticals recently released its 10-Q report. The Cambridge, Massachusetts-based biopharmaceutical company develops medicines in cellular metabolism, with a commercial focus on PYRUKYND, a pyruvate kinase activator approved in the U.S. for hemolytic anemia in adults with PK deficiency and for anemia in adults with non-transfusion-dependent and transfusion-dependent alpha* or beta-thalassemia under the brand AQVESME. It is also advancing PYRUKYND in sickle cell disease and pediatric PK deficiency, while developing AG-181, AG-236 and cevidoplenib for other rare and immune-mediated diseases.
In Item 2, Management’s Discussion and Analysis, Agios said its six months ended June 30, 2026 net loss was $199.8 million, compared with $201.3 million a year earlier, and its accumulated deficit reached $761.5 million. The company said it expects to keep spending heavily on commercialization and development as it advances PYRUKYND, AQVESME, AG-181, AG-236 and cevidoplenib.
Agios said product revenue continues to come from U.S. sales of PYRUKYND and AQVESME through specialty distributors and specialty pharmacies. It also noted international commercialization agreements for PYRUKYND, including the July 2024 NewBridge deal covering Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates, and the June 2025 Avanzanite agreement covering the European Economic Area, Switzerland and the U.K.
The company highlighted a June 1, 2026 license agreement with Oscotec for cevidoplenib, under which it recorded $25.0 million of in-process research and development expense in the second quarter. Agios said it may owe up to $140.0 million in development and regulatory milestones in the U.S. and Europe, plus sales milestones and tiered royalties.
On mitapivat, Agios said it filed a supplemental NDA in May 2026 for accelerated approval in sickle cell disease, received priority review, and was assigned a PDUFA date of November 1, 2026. To support that filing, it started the phase 3 REIGNITE trial, which is designed to measure reduction in transfusion burden in patients age 12 and older with sickle cell disease. As a result of these announcements, the company's shares have moved -10.54% on the market, and are now trading at a price of $31.3201. For more information, read the company's full 10-Q submission here.
